Year |
Citation |
Score |
2019 |
Louphrasitthiphol P, Ledaki I, Chauhan J, Falletta P, Siddaway R, Buffa FM, Mole DR, Soga T, Goding CR. MITF controls the TCA cycle to modulate the melanoma hypoxia response. Pigment Cell & Melanoma Research. PMID 31207090 DOI: 10.1111/pcmr.12802 |
0.39 |
|
2018 |
Lisboa da Motta L, Ledaki I, Haider S, De Bastiani M, Baban D, Stefan K, Klamt F, Heery D, Harris A, McIntyre A. PO-276 Histone acetylation readers BET in hypoxia adaptation in triple negative breast cancer (TNBC) Esmo Open. 3: A335. DOI: 10.1136/esmoopen-2018-EACR25.790 |
0.308 |
|
2016 |
da Motta LL, Ledaki I, Purshouse K, Haider S, De Bastiani MA, Baban D, Morotti M, Steers G, Wigfield S, Bridges E, Li JL, Knapp S, Ebner D, Klamt F, Harris AL, et al. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene. PMID 27292261 DOI: 10.1038/onc.2016.184 |
0.734 |
|
2016 |
McIntyre A, Hulikova A, Ledaki I, Snell C, Singleton D, Steers G, Seden P, Jones D, Bridges E, Wigfield S, Li JL, Russell A, Swietach P, Harris AL. Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. Cancer Research. PMID 27197160 DOI: 10.1158/0008-5472.Can-15-1862 |
0.644 |
|
2015 |
Ledaki I, McIntyre A, Wigfield S, Buffa F, McGowan S, Baban D, Li JL, Harris AL. Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotarget. 6: 19413-27. PMID 26305601 |
0.76 |
|
2013 |
McIntyre A, Hulikova A, Ledaki I, Seden P, Turley H, Jones D, Russell A, Swietach P, Harris AL. Abstract 4053: Hypoxic trans-activation of sodium dependent bicarbonate co-transporters regulates pH in 3D spheroids and promotes growth. Cancer Research. 73: 4053-4053. DOI: 10.1158/1538-7445.Am2013-4053 |
0.728 |
|
2012 |
McIntyre A, Patiar S, Wigfield S, Li JL, Ledaki I, Turley H, Leek R, Snell C, Gatter K, Sly WS, Vaughan-Jones RD, Swietach P, Harris AL. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3100-11. PMID 22498007 DOI: 10.1158/1078-0432.CCR-11-1877 |
0.604 |
|
2010 |
Sivridis E, Koukourakis MI, Zois CE, Ledaki I, Ferguson DJ, Harris AL, Gatter KC, Giatromanolaki A. LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas. The American Journal of Pathology. 176: 2477-89. PMID 20382705 DOI: 10.2353/ajpath.2010.090049 |
0.619 |
|
2009 |
Yang J, Ledaki I, Turley H, Gatter KC, Montero JC, Li JL, Harris AL. Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases. Annals of the New York Academy of Sciences. 1177: 185-97. PMID 19845621 DOI: 10.1111/j.1749-6632.2009.05027.x |
0.689 |
|
Low-probability matches (unlikely to be authored by this person) |
2008 |
Attard G, Olmos D, Arkenau HT, Ledaki I, Carden CP, Reid AH, Ang J, Fong PC, Parker C, De Bono JS. Pre- and post-treatment circulating tumor cell counts (CTCc) and overall survival (OS) in castration-resistant prostate cancer (CRPC): The Royal Marsden Hospital (RMH) experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5072. PMID 27948773 DOI: 10.1200/jco.2008.26.15_suppl.5072 |
0.235 |
|
2008 |
Shepherd CJ, Rizzo S, Ledaki I, Davies M, Brewer D, Attard G, de Bono J, Hudson DL. Expression profiling of CD133+ and CD133- epithelial cells from human prostate. The Prostate. 68: 1007-24. PMID 18398820 DOI: 10.1002/pros.20765 |
0.215 |
|
2009 |
Attard G, Rizzo S, Ledaki I, Clark J, Reid AHM, Thompson A, Khoo V, De Bono JS, Cooper CS, Hudson DL. A novel, spontaneously immortalized, human prostate cancer cell line, bob, offers a unique model for pre-clinical prostate cancer studies Prostate. 69: 1507-1520. PMID 19544327 DOI: 10.1002/pros.20997 |
0.192 |
|
2009 |
Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, Reid AH, A'Hern R, Fong PC, Oomen NB, Molife R, Dearnaley D, Parker C, Terstappen LW, de Bono JS. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 20: 27-33. PMID 18695026 DOI: 10.1093/annonc/mdn544 |
0.181 |
|
2008 |
Yap TA, Harris D, Barriuso J, Wright M, Riisnaes R, Clark J, Ledaki I, Savage R, Chen T, De Bono JS. Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3584. PMID 27949681 DOI: 10.1200/jco.2008.26.15_suppl.3584 |
0.177 |
|
Hide low-probability matches. |